Shares of Emergent BioSolutions Inc. were up 1.7% in premarket trading on Tuesday after the company said the Food and Drug Administration is reviewing its application for over-the-counter Narcan. The spray is used to treat known or suspected opioid overdoses. The regulator is set to make its decision whether to approve the application by March 29. The FDA indicated in November that it would consider approving OTC use of Narcan for the first time. Emergent’s stock has tumbled 73.9% this year, while the broader S&P 500 is down 16.1%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.